¿ËÈÕ£¬£¬ÄϹ¬NG28¼¯ÍÅ»ù´¡Ò½Ñ§Ôº³Â½¨º£¿£¿ÎÌâ×éÁªºÏÖйú¿ÆѧԺÉîÛÚÏȽøÊÖÒÕÑо¿ÔºÔÚCell×Ó¿¯Cell Reports MedicineÉϽÒÏþÌâΪ¡°Specific macrophage RhoA targeting CRISPR-Cas9 for mitigating osteoclastogenesis -induced joint damage in inflammatory arthritis¡±µÄÑо¿ÊÂÇé¡£¡£¡£

ͼ1.ÎÄÕÂÔÚÏß½Øͼ

Àà·çʪÊàŦÑ×ÊÇÒ»ÖÖ³£¼û×ÔÉíÃâÒß¼²²¡£¬£¬ÃâÒßϵͳ»á¹¥»÷¿µ½¡µÄÊàŦ×éÖ¯£¬£¬±ê¼ÇÐÔÌØÕ÷ΪÊàŦ»¬Ä¤Ñ׺ÍÊàŦ¹ÇÆÆË𡣡£¡£µ±Ñ×Ö¢Òò×ÓÌ«¹ý±í´ïÒýÆðÑ×֢ϸ°û´ó×Ú½þÈëÊàŦ£¬£¬´¥·¢»¬Ä¤Ñ×Ö¢²¢µ¼ÖÂѪ¹ÜôèÐγÉ£¬£¬½øÒ»²½ÇÖÊ´Èí¹Ç¼°¹Ç×éÖ¯£¬£¬µ¼Ö²»¿ÉÄæµÄÊàŦËðÉË£¬£¬ÖÐÍíÆÚÖ²ÐÂʸߴï60%-70%¡£¡£¡£ÊàŦ»¬Ä¤¾ÞÊÉϸ°ûÊÇÒ»°Ñ¡°Ë«Èн£¡±£¬£¬¼ÈÊÇ¡°ÆÆËðÕß¡±£º£º£º´ÙÑס¢¡¢ÆƹÇ£»Ò²ÊÇ¡°Ïû·ÀÔ±¡±£º£º£º¿¹Ñ׺ÍÔö½ø³É¹ÇÌìÉú¡£¡£¡£Àà·çʪÊàŦÑ×±£´æÃâÒßʧºâ£¬£¬´Ì¼¤ÓÕµ¼¾ÞÊÉϸ°ûÏòÆÆËðÕß½Çɫת»¯£¬£¬Çý¶¯¼²²¡¶ñÐÔ¿ªÕ¹¡£¡£¡£Òò´Ë£¬£¬ÔõÑù¾«×¼×èÖ¹»òÄæת»¬Ä¤¾ÞÊÉϸ°ûµÄµ¹ÔËת»¯£¬£¬ÊÇÀà·çʪÊàŦÑ×ÕïÁÆÁìÓòµÄÇ°ÑØÈÈÃÅ¿ÎÌâ£¬£¬È»¶øÓÉÓÚȱ·¦¶Ô»¬Ä¤¾ÞÊÉϸ°ûÌØÒìʶ±ðºÍµ÷¿ØÊÖ¶Î£¬£¬¶øÃæÁÙÖØ´óÌôÕ½¡£¡£¡£

±¾Ñо¿Ê×ÏÈͨ¹ýµ¥Ï¸°ûÊý¾ÝÆÊÎöÒÔ¼°»ùÒòÇóýСÊóÄ£×ÓÈ·¶¨ÁËRasͬԴ»ùÒò¼Ò×å³ÉÔ± A£¨RhoA£©ÊÇÓÕµ¼¾ÞÊÉϸ°ûÆƹÇϸ°ûÌìÉúµÄÒªº¦°Ðµã¡£¡£¡£ÔÚ½ºÔ­ÓÕµ¼ÊàŦÑ×Ä£×ÓÖÐ£¬£¬RhoA-cKOСÊóÕ¹ÏÖ³öÏÔÖø¼õÇáµÄÊàŦÖ×ÕÍ¡¢¡¢½ÏµÍµÄƽ¾ùצºñ¶È¼°ÁÙ´²ÆÀ·Ö£¬£¬Åú×¢¾ÞÊÉϸ°ûÖÐRhoAµÄȱʧÄÜÔ¤·ÀÑ×Ö¢ºÍÊàŦÖ×ÕÍ¡£¡£¡£»ùÓÚ´Ë·¢Ã÷£¬£¬±¾ÍŶÓÊ״οª·¢ÁËÒ»ÖÖ³ÆΪÌØÒìÐÔ¾ÞÊÉϸ°û RhoA °ÐÏò£¨SMART£©µÄÕ½ÂÔ£¬£¬ÆäÖи»º¬Á×Ö¬õ£Ë¿°±ËᣨPS£©µÄ¾ÞÊÉϸ°ûĤ±»Éè¼ÆÓÃÓÚµÝËͺ¬ÓоÞÊÉϸ°ûÌØÒìÐÔÆô¶¯× CRISPR-Cas9 ÖÊÁ££¨SMART-Cas9£©¡£¡£¡£»¬Ä¤¾ÞÊÉϸ°ûRhoAµÄÀÖ³ÉÇóý£¬£¬²»µ«×è¶ÏÁ˾ÞÊÉϸ°ûÉø͸Ñ×Ö¢Òò×Ó£¬£¬ÖØËÜÃâÒßƽºâ£¬£¬´ÓÔ´Í·ÉϽµµÍÑ­»·¾ÞÊÉϸ°ûÔÚÊàŦµÄȺ¼¯£¬£¬Í¬Ê±Í¨¹ýµ÷¿ØRho/ROCKÐźÅͨ·¸ßЧӰÏìϸ°û¹Ç¼Ü¹¦Ð§£¬£¬ÒÖÖƻµÄ¾ÞÊÉϸ°ûÏòÆƹÇϸ°û·Ö»¯£¬£¬Èçϸ°ûÈںϡ¢¡¢¹Ç»ùÖʽµ½âµÈ¡£¡£¡£´Ó¶øïÔÌ­ÊàŦµÄÈí¹ÇºÍ³É¹ÇµÄÆÆË𡣡£¡£

ͼ2.Ñо¿Ë¼Ð÷ʾÒâͼ

ÄϹ¬NG28¼¯ÍÅ»ù´¡Ò½Ñ§Ôº¸ßÌõÀíÈ˲ų½¨º£ÎªÂÛÎĵÚÒ»×÷Õß£¬£¬Öйú¿ÆѧԺÉîÛÚÏȽøÊÖÒÕÑо¿ÔºÕÅÅôÑо¿Ô±µÈΪÂÛÎÄͨѶ×÷Õß¡£¡£¡£¸ÃÑо¿»ñµÃ¹ú¼ÒÖصãÑз¢ÍýÏë¡¢¡¢¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðί¡¢¡¢Ò½Ñ§³ÉÏñ¿ÆѧÓëÊÖÒÕϵͳÌìÏÂÖصãʵÑéÊÒ¡¢¡¢Öйú¿ÆѧԺÇà´Ù»á¡¢¡¢¹ã¶«Ê¡»ù´¡ÓëÓ¦Óûù´¡Ñо¿»ù½ðί¡¢¡¢ÉîÛÚÊпƼ¼ÍýÏëµÈÏîÄ¿Ö§³Ö¡£¡£¡£